REVIEW

CB₂ cannabinoid receptors as an emerging target for demyelinating diseases: from neuroimmune interactions to cell replacement strategies

Á Arévalo-Martín¹, D García-Ovejero¹, O Gómez¹, A Rubio-Araiz¹, B Navarro-Galve¹, C Guaza², E Molina-Holgado¹ and F Molina-Holgado³

¹Laboratory of Neuroinflammation, Unidad de Neurología Experimental, Hospital Nacional de Paraplégicos (SESCAM), 45071 Toledo, Spain-Research Unit associated to the Instituto Cajal (CSIC), Madrid, Spain; ²Neuroimmunology Group, Instituto Cajal (CSIC), Madrid, Spain and ³King's College London, The Wolfson Centre for Age-Related Diseases, London, UK

Amongst the various demyelinating diseases that affect the central nervous system, those induced by an inflammatory response stand out because of their epidemiological relevance. The best known inflammatory-induced demyelinating disease is multiple sclerosis, but the immune response is a common pathogenic mechanism in many other less common pathologies (e.g., acute disseminated encephalomyelitis and acute necrotizing haemorrhagic encephalomyelitis). In all such cases, modulation of the immune response seems to be a logical therapeutic approach. Cannabinoids are well known immunomodulatory molecules that act through CB₁ and CB₂ receptors. While activation of CB₁ receptors has a psychotropic effect, activation of CB₂ receptors alone does not. Therefore, to bypass the ethical problems that could result from the treatment of inflammation with psychotropic molecules, considerable effort is being made to study the potential therapeutic value of activating CB₂ receptors. In this review we examine the current knowledge and understanding of the utility of cannabinoids as therapeutic molecules for inflammatory-mediated demyelinating pathologies. Moreover, we discuss how CB₂ receptor activation is related to the modulation of immunopathogenic states.

British Journal of Pharmacology (2008) **153**, 216–225; doi:10.1038/sj.bjp.0707466; published online 24 September 2007

Keywords: endocannabinoid system; neuroinflammation; oligodendrocyte; multiple sclerosis; neural stem cells

Abbreviations: APCs, antigen-presenting cells; CNS, central nervous system; CREAE, chronic relapsing experimental allergic encephalomyelitis; CXCL12, stromal cell-derived factor; DCs, dendritic cells; DHT, delayed-type hypersensitivity; EAE, experimental allergic encephalomyelitis; ICAM-1, intercellular adhesion molecule-1; IFN- γ , interferon- γ ; IL, interleukin; IL-1ra, interleukin-1 receptor antagonist; KO, knockout; LPS, lipopolysaccharide; MBP, myelin basic protein; MHC, major histocompatibility complex; MOG, myelin oligodendroglial glycoprotein; MS, multiple sclerosis; NSCs, neural stem cells; PI3K/Akt, phosphoinositide 3-kinase/protein kinase B; PNS, peripheral nervous system; PSA-NCAM, polysialylated neural cell adhesion molecule; SGZ, subgranular zone; SVZ, subventricular zone; Ths, T-helper cells; TMEV-IDD, Theiler's murine encephalomyelitis virus-induced demyelinating disease; TNF- α , tumour necrosis factor alpha; VCAM-1, vascular cellular adhesion molecule-1; WT, wild type; Δ^9 -THC, delta-9-tetrahydrocannabinol

Introduction

Demyelination is the loss of the myelin sheath that surrounds axons and it may affect both the central nervous system (CNS) and peripheral nervous system (PNS). Demyelinating pathologies may have a primary genetic aetiology (leukodystrophies) or may be the secondary effect of

infections, vascular alterations, toxic insults or inflammatory reactions. Regardless of the cause, the result will be the total or partial loss of function in the demyelinated area, depending on the region of the nervous system affected. In this review we shall focus on the CNS demyelinating diseases in which inflammation plays a role in their pathogenesis, like multiple sclerosis (MS). However, we will also discuss other effects mediated by CB₂ that are fundamental in demyelinating diseases, including neuronal and glial protection, the regulation of stem/precursor cells and cell replacement. MS is the most frequent neurological disease in young adults. In addition to myelin loss, there is also neuronal damage in MS that further contributes to the symptomatology

Correspondence: Dr E Molina-Holgado, Hospital Nacional de Paraplégicos (SESCAM), Finca La Peraleda, s/n, 45071 Toledo, Spain.

E-mail: emolina@fundacionhnp.org and F Molina-Holgado, King's College London, The Wolfson Centre for Age-Related Diseases, Hodking Building, Guy's Campus, London SE1 1UL, UK.

E-mail: francisco.molina-holgado@kcl.ac.uk

Received 2 July 2007; revised 16 August 2007; accepted 20 August 2007; published online 24 September 2007

(Ferguson *et al.*, 1997; Mews *et al.*, 1998; Trapp *et al.*, 1998, 1999). Even though several hypotheses have been proposed to explain its aetiopathology, this issue remains unresolved. Epidemiological studies suggest that MS occurs in a genetically susceptible population that has been in contact with an environmental factor, most probably a viral infection. This triggers an immune response that, by diverse mechanisms is finally directed towards myelin self-peptides (Kurtzke, 1993; Johnson, 1994; Coraddu *et al.*, 1998; Haines *et al.*, 1998). Accordingly, the CSF of MS patients contains antibodies against myelin basic protein (MBP) and myelin oligodendroglial glycoprotein (MOG; Olsson and Nilsson, 1979; Miller *et al.*, 1983). This autoimmune response against myelin peptides has been reproduced in animal models of MS, such as experimental allergic encephalomyelitis (EAE) and Theiler's murine encephalomyelitis virus-induced demyelinating disease (TMEV-IDD; Rauch *et al.*, 1987; Rodriguez *et al.*, 1988; Fujinami, 1989; Yamada *et al.*, 1990). In both MS- and EAE-, activated lymphocytes are detected that recognize several epitopes of myelin proteins and these self-reactive clones have been reported to be involved in the pathogenesis of EAE and TMEV-IDD (Gerety *et al.*, 1994; Steinman, 1996; Schmidt *et al.*, 1997; Pope *et al.*, 1998; Hellings *et al.*, 2002). The main reason for inflammatory-mediated damage is thought to be the release of reactive oxygen and nitrogen species by immune cells, as well as that of proteases, which directly mediate cell damage (Correa *et al.*, 2005a, b). In addition, immune cells release cytotoxic/cytostatic cytokines, that not only cause damage but that may also enhance the release of more reactive species and glutamate by the cells in the surrounding tissue (the pathogenic mechanisms of demyelinating diseases are summarized in Figure 1). Modulation of the immune response could therefore be an important therapeutic approach to treat demyelinating conditions.

Since the late 1970s, it was clear that the psychoactive compounds of *Cannabis sativa*, such as delta-9-tetrahydrocannabinol (Δ^9 -THC), modulate the inflammatory response (Zimmerman *et al.*, 1977; Smith *et al.*, 1978). In the following years, numerous studies showed that cannabinoids increased the susceptibility of animals to experimentally induced infections, as these molecules acted as anti-inflammatory drugs. The discovery of this undesirable effect of cannabinoids within the context of infection led to the idea that they could be used against inflammation in diseases like MS. Indeed, in the 1980s, a cannabinoid agonist was first shown to be effective in a CNS demyelinating pathology (Lyman *et al.*, 1989). In this study, animals pretreated with Δ^9 -THC displayed a delay in the onset of the symptoms and a reduction in severity when EAE was subsequently induced. In corresponding histological studies, a decrease in cell infiltration into the spinal cord was observed, which correlated with the symptomatology of the inflammatory process. The identification of the so-called peripheral cannabinoid receptor (Munro *et al.*, 1993) and further studies on the function of this receptor identified the new CB₂ receptor as the major participant in cannabinoid-mediated immune modulation. Indeed, the CB₂ receptor was found to be expressed primarily in cells of the immune and haematopoietic systems (Munro *et al.*, 1993) although more

recently it was found in the brain (Van Sickle *et al.*, 2005; Gong *et al.*, 2006). CB₂ receptors are G-protein-coupled receptors that primarily associate with the Gi/o subtypes of G proteins, and they activate signalling pathways that may involve adenylate cyclase inhibition or activation of mitogen-activated protein kinases (reviewed in Howlett and Mukhopadhyay, 2000; Pacher *et al.*, 2006; Fernandez-Ruiz *et al.*, 2007).

The effects of CB₂ activation on demyelination through modulation of the inflammatory response

The first studies on the potential therapeutic role of cannabinoids in demyelinating diseases were aimed at evaluating its usefulness as a symptomatic treatment for spasticity and tremor in patients with MS (Clifford, 1983; Ungerleider *et al.*, 1987). However, the involvement of CB₁ or CB₂ was not assessed since they were yet to be cloned at that time. While the administration of a CB₂ agonist to mice with chronic relapsing experimental allergic encephalomyelitis (CREAE) ameliorated spasticity, the use of a CB₂ antagonist worsened it (Baker *et al.*, 2001). As well as using CB₂ agonists for symptomatic treatment of demyelinating pathologies, cannabinoids may serve as therapeutic agents. In this scenario, CB₂ is expressed in MS plaques by microglia, lymphocytes and astrocytes (Benito *et al.*, 2007). Indeed, intraperitoneal injection of a selective CB₂ agonist over 10 days to mice with established TMEV-IDD improves their motor function by modulating microglia and lymphocyte infiltration into the spinal cord (Arévalo-Martín *et al.*, 2003). As with MS, there is an autoimmune response against myelin peptides in TMEV-IDD that contribute to the pathology (Gerety *et al.*, 1994; Merrill and Benveniste, 1996; Steinman, 1996). In essence, myelin-specific CD4⁺ peripheral T cells are activated and enter the spinal cord where, after recognizing their specific epitope, they differentiate into a T-helper cell (Th1) phenotype and elaborate a delayed-type hypersensitivity (DTH) response (Figure 1). In DTH responses, not only the immune cells are involved but also, the surrounding tissue cells respond to the signals released by the immune system. CB₂ receptors are expressed by all cells in the immune system both in humans and rodents (Galiegue *et al.*, 1995; Lee *et al.*, 2001; Matias *et al.*, 2002), as well as by resident CNS cells. We shall analyse, here, how CB₂ receptor activation can improve an immune-mediated demyelinating disorder through its effects on the following cell types: CD4⁺ T cells, B lymphocytes, dendritic cells (DCs), microglia/macrophages and astrocytes. However, it should be noted here that CB₂ is highly inducible and its presence or absence in culture models may or may not reflect the native situation *in vivo*.

CD4⁺ T cells

Treatment of TMEV-IDD mice with a CB₂ agonist reduces the infiltration of CD4⁺ T cells to the spinal cord (Arévalo-Martín *et al.*, 2003). Among other effects, this could be the result of inhibiting the migration of these cells from the periphery to the CNS since the CB₂ selective ligands JWH-133 and JWH-015 inhibit stromal cell-derived factor

Figure 1 Hypothetic immune-mediated demyelinating disease pathogenesis. Primed CD4⁺ T lymphocytes migrate to the CNS through blood vessels enriched in adhesion molecules. Once in the CNS, DCs or macrophages/microglia acting as APC present the antigen to antigen-specific CD4⁺ lymphocytes. Depending on the environmental signals that these cells receive, the CD4⁺ lymphocytes acquire different T helper (Th) phenotypes. Th1 cells will establish an antigen-specific DTH response that will lead to the liberation of several cytotoxic molecules by the Th1 themselves, astrocytes and microglia/macrophages. In addition, the generation of the Th2 phenotype will result in the activation of infiltrated B cells into plasma cells that will secrete antibodies against myelin antigens. This response has been related both with oligodendroglial damage and recovery. Even though their pathogenic contribution to MS and EAE is not clear, CD8⁺ T cells recognize specific antigens and they may elaborate a cytotoxic response against the cells that presented the antigen. CNS, central nervous system; DCs, dendritic cells; DTH, delayed-type hypersensitivity; EAE, experimental allergic encephalomyelitis; LFA-1, lymphocyte function-associated antigen-1; MS, multiple sclerosis; VLA-4, very late activation antigen-4.

(CXCL12)-induced chemotaxis and transendothelial migration (Ghosh *et al.*, 2006; Coopman *et al.*, 2007). The reduced infiltration of CD4⁺ T cells into the spinal cord may also be explained through CB₂ activation to induce apoptosis of these cells (Sanchez *et al.*, 2006; Lombard *et al.*, 2007). Remarkably, some of the effects induced by CB₂ agonists are not completely blocked by CB₂ antagonists and they seem to be independent of CB₁ receptors (Sanchez *et al.*, 2006). Thus, it should be borne in mind that there is increasing evidence of non-CB₁- and non-CB₂-mediated effects of many cannabinoids. Nevertheless, here we will focus on the studies where the effects are mediated partially or entirely by CB₂ receptors.

Whether by inhibiting the migration of leukocytes or promoting the apoptosis of these cells, the effect of the reduced infiltration of these cells into the CNS is beneficial as there is a decrease in the release of Th1 cytokines (interferon- γ (IFN- γ), tumour necrosis factor- α (TNF- α) or interleukin-12 (IL-12)) into the surrounding tissue, which is involved in

tissue damage. It is known that cannabinoids alter the profile of cytokine expression from a Th1 to a Th2 phenotype in a CB₂-dependent manner (Yuan *et al.*, 2002). In addition, the treatment of TMEV-IDD mice with the non-selective CB₁ and CB₂ agonist WIN 55212-2 inhibits the myelin-specific DTH response and the release of IFN- γ from CD4⁺ T cells (Croxford and Miller, 2003). IFN- γ has been shown to exacerbate MS, reducing the survival of oligodendrocytes and affecting normal myelination (Panitch *et al.*, 1987; Corbin *et al.*, 1996; Horwitz *et al.*, 1997; Molina-Holgado *et al.*, 2001). In addition IFN- γ induces the expression of the vascular cellular adhesion molecule-1 (VCAM-1) by endothelial cells, which favours the access of activated lymphocytes to the CNS (Groves *et al.*, 1993; Weiser *et al.*, 2007). Therefore, reducing the release of IFN- γ by the Th1 cells could itself block the 'calling' signal and therefore, decrease the migration of more primed T cells to the CNS that would amplify the damage.

B lymphocytes

As commented above, antibodies against myelin proteins are detected in both MS patients and in EAE and TMEV-IDD mice. Although their pathological contribution is not clear, since autoantibodies have been related both with damage and recovery (Rodriguez and Lennon, 1990; Brosnan and Raine, 1996), cannabinoids modulate the function of the cells that produce them through a mechanism that involves CB₂. For instance, cannabinoids are involved in the maturation of B lymphocytes to antibody-secreting plasma cells, and they are known to induce the apoptosis of these cells (Carayon *et al.*, 1998; Lombard *et al.*, 2007).

Microglia/macrophages

In both MS patients and animal models of the disease, activated microglia/macrophages have been related to tissue damage. The release of reactive oxygen and nitrogen species, seem to be two critical events involved in the pathogenesis of these cells, producing severe damage to myelin and toxicity in oligodendroglia and neurons (Chia *et al.*, 1983; Konat and Wiggins, 1985; Rodriguez and Quddus, 1986; Liuzzi *et al.*, 1995; Molina-Hogado *et al.*, 2001). Treatment of activated microglia cultures with anandamide, UCM707 (an endocannabinoid uptake blocker) or WIN 55212-2, decreases the expression of the inducible NOS-2 and the production of nitrites in a CB₁- and CB₂-dependent manner (Ortega-Gutierrez *et al.*, 2005; Eljaschewitsch *et al.*, 2006). In addition, microglia and macrophages produce several cytokines considered to be pro-inflammatory, such as TNF- α , IL-1 β or IL-12. Through CB₂ receptors, cannabinoids inhibit the expression of TNF- α , IL-1 β and the p40 subunit of IL-12 and IL-23 by microglia/macrophages (Klegeris *et al.*, 2003; Correa *et al.*, 2005a, b). TNF- α causes neuronal death through an excitotoxic mechanism and recruits more lymphocytes to the CNS by upregulating the expression of VCAM-1 and intercellular adhesion molecule-1 (ICAM-1) on endothelial cells (Dobbie *et al.*, 1999; Weiser *et al.*, 2007). The benefits derived from inhibiting IL-1 β release may be related to the increase in NMDA receptor-mediated intracellular calcium provoked by this cytokine, which in turn augments glutamate-mediated neurodegeneration (Viviani *et al.*, 2003). On the other hand, cannabinoids may abrogate the beneficial effects of IL-1 β , which promotes the survival of mature oligodendrocytes and therefore, impedes demyelination (Vela *et al.*, 2002). IL-12 is necessary for the differentiation of the lymphocytes that enter into the CNS in the Th1 phenotype, explaining the therapeutic effect of CB₂-mediated inhibition of the p40 subunit of IL-12 in monocytic cells (Shevach *et al.*, 1999; Correa *et al.*, 2005a, b). In addition, the p40 subunit is a constituent of IL-23, which is directly involved in the generation of the Th17 lymphocyte phenotype. This has recently been uncovered as a major participant in tissue damage (Langrish *et al.*, 2005; Kroenke and Segal, 2007).

Microglia/macrophages are also involved in antigen presentation, which is necessary for the activation of primed lymphocytes that enter the CNS. Treatment of TMEV-IDD mice with a CB₂ agonist decreases microglial activation and major histocompatibility complex-II (MHC-II) expression in

the spinal cord (Arévalo-Martin *et al.*, 2003; Ortega-Gutierrez *et al.*, 2005). Finally, specific stimulation of CB₂ receptors by JWH-015 suppresses IFN- γ -induced CD40 expression, which is involved in phagocytosis, antigen presentation and the production of cytokines. CD40 is becoming considered as a new therapeutic target for experimental autoimmune encephalomyelitis (EAE), since blocking CD40-CD154 interactions with a neutralizing antibody diminishes murine EAE disease activity (Ehrhart *et al.*, 2005 and references therein).

It should be noted that CB₂ expression is highly inducible in macrophages or microglia, and its levels *in vitro* depend on the local environment and the combination of inflammatory molecules (Carlisle *et al.*, 2002; Maresz *et al.*, 2005). In addition, *in vivo* CB₂ is not expressed equally in all microglial populations, but rather it is predominantly present in perivascular or activated microglia (Benito *et al.*, 2003; Nunez *et al.*, 2004). This variability in the expression of CB₂ *in vitro* and *in vivo* must be taken into account when extrapolating the effects mediated by CB₂ in culture models to the *in vivo* situation, not only for microglia but also for other cell types.

Dendritic cells

DCs, the major antigen-presenting cells (APCs), drive the cellular fate of lymphocytes and therefore, they are critical for the development of immune responses. These cells have been involved in the pathogenesis of MS and related animal models (Greter *et al.*, 2005) even though there is no direct evidence that activation of CB₂ receptors modulates their activity in MS or in animal models. However, CB₂ receptor activation does induce apoptosis of these cells, as well as promoting their migration to lymph nodes (Maestroni, 2004).

Astrocytes

Astrocytes express CB₁ and CB₂ receptors and they respond to cytokines secreted by the immune cells by regulating the production of molecules involved both in the bystander injury and in the protection of CNS tissue (Molina-Holgado F *et al.*, 2002; Sheng *et al.*, 2005). Among these molecules, astrocytes express NOS-2 and they produce NO in response to several inflammatory signals. Cannabinoids inhibit the release of nitrites by astrocytes through a mechanism involving the CB₂ receptor (Molina-Holgado *et al.*, 1997; Molina-Holgado F *et al.*, 2002; Sheng *et al.*, 2005). In these cells, cannabinoids also inhibit the inflammation-induced expression of TNF- α , IL-1 β and IL-6 through CB₁ and CB₂ receptors (Molina-Holgado *et al.*, 1997, 1998; Ortega-Gutierrez *et al.*, 2005). The implications of modulating TNF- α and IL-1 β expression in inflammatory-demyelinating diseases have already been discussed. Regarding IL-6, this controversial cytokine is thought to be involved in disease development, in the protection of both neurons and oligodendroglial cells from excitotoxicity, and in remyelination (Rodriguez *et al.*, 1994; Okuda *et al.*, 1998; Pizzi *et al.*, 2004). Regarding excitotoxic damage, it was recently shown that cannabinoids can prevent axonal damage in a viral model of MS, interfering with the excitotoxic component in

the progression of this disease in a way that requires activation of CB₂ receptors (Docagne *et al.*, 2007).

CB₂ activation affects remyelination through modulation of the inflammatory response

In experimental models of demyelination there is, both neurological and histopathological, evidence of the therapeutic benefit of cannabinoids. Most data indicate that the activation of CB₁ or CB₂ receptors reduces deficits such as spasticity, tremor or neuropathic pain (Baker *et al.*, 2000), whereas CB₂ receptors also regulate inflammatory aspects related to disease progression (Maresz *et al.*, 2007). Recent studies show that demyelination and axonal defects that initially occur after humoral and cellular immune-mediated attacks to elements of the CNS are affected by cannabinoid treatment. We previously reported extensive remyelination of the spinal cord in TMEV-infected mice, which paralleled the functional recovery of mice treated with WIN 55212-2, ACEA and JWH-015, CB₁/CB₂, CB₁ and CB₂ receptor agonists, respectively (Arévalo-Martín *et al.*, 2003). In this model, cannabinoid-induced attenuation of the inflammatory response was linked to axon remyelination. Oligodendrocyte death and the resulting destruction of myelin plays an important role in axonal degeneration, as demyelinated axons are highly vulnerable to oxidative stress and to cytokine and glutamate toxicity (Werner *et al.*, 2001). Similarly, oligodendrocytes are sensitive to microglial-derived free-radicals and mediators of inflammation (Molina-Holgado *et al.*, 2001; Back *et al.*, 2002; Li *et al.*, 2005). Therefore, strategies aimed at reducing or slowing down the demyelination and neurodegeneration process will certainly be beneficial in MS.

It is now well accepted that once oligodendrocytes have lost their myelin membranes, they are unable to remyelinate axons even if they survive the insult (Keirstead and Blakemore, 1997). Consequently, oligodendrocyte progenitors located in the brain parenchyma and as stem cells in the subventricular zone (SVZ) are recruited to demyelinated areas following experimental demyelination and in MS to remyelinate naked axons (Keirstead and Blakemore, 1999; Chang *et al.*, 2000; Menn *et al.*, 2006). The specific action of cannabinoids in neural stem cells is described in the next section. However, the failure in remyelination could either be due to the constant presence of lymphocytes invading the CNS, which release IFN- γ or to the activated microglia/astrocytes that produce IL-1 β , TNF- α and IL-6, among other mediators. Cannabinoids may directly enhance myelin repair by acting on oligodendrocyte progenitors, or they may act indirectly by inhibiting the immune response that might be contributing to demyelination or hampering remyelination.

The synthetic cannabinoid agonists HU210 or WIN 55212-2 act on both CB₁ and CB₂ receptors to protect oligodendrocytes from apoptosis produced by deprivation of trophic support, a mechanism dependent on phosphoinositide 3-kinase/protein kinase B (PI3K/Akt) signalling (Molina-Holgado E *et al.*, 2002). Moreover, cannabinoids suppress the production of inflammatory molecules by astrocytes

and microglial cells including IL-1 β , TNF- α and NO (Molina-Holgado *et al.*, 1997; Molina-Holgado E *et al.*, 2002; Puffenbarger *et al.*, 2000; Cabral *et al.*, 2001), as well as enhancing the release of the anti-inflammatory cytokines IL-4, IL-10, IL-6 and interleukin-1 receptor antagonist (IL-1ra) (Molina-Holgado *et al.*, 1998, 2003; Klein *et al.*, 2000).

Apoptotic death of oligodendrocytes occurs following treatment with IFN- γ or TNF- α (Vartanian *et al.*, 1995; Baerwald and Popko, 1998; Ye and D'Ercole, 1999). Moreover, NO released by microglia or generated from exogenous NO donors is known to induce oligodendrocyte death (Merrill *et al.*, 1993). In contrast, IL-1 β is not toxic for oligodendrocytes in pure culture, but it does produce apoptosis of oligodendrocytes in mixed glial cultures containing astrocytes and microglia. However, this apoptosis can be blocked by antagonists of AMPA/kainate glutamate receptors (Takahashi *et al.*, 2003). Interestingly, the cannabinoid HU-210 reduced neural cell death in response to S-AMPA or NMDA receptor activation, although neurons from IL-1ra knockout (KO) mice were not protected. These results suggest that the neuroprotective and anti-inflammatory effects of cannabinoids are mediated by the release of endogenous IL-1ra in primary neurons or glial cells *in vitro*. The specific CB₁ and CB₂ receptor antagonists (SR-141716A and SR-144528, respectively) abrogated lipopolysaccharide (LPS)-induced IL-1ra release, implicating both CB receptors in this effect (Molina-Holgado *et al.*, 2003). However, in chronic relapsing EAE only cannabinoid agonists acting through CB₁ receptors provide significant neuroprotection (Pryce *et al.*, 2003).

The anti-inflammatory cytokines, IL-4 and IL-10 and their receptors are present in oligodendroglial cells (Molina-Holgado *et al.*, 2001), and some of the effects attributed to these cytokines in models of MS (Kennedy *et al.*, 1992) may have a direct influence on oligodendrocytes. Remarkably, IL-10 offered protection against oligodendroglial death evoked by LPS/IFN- γ . These data raise the question of whether IL-10 may play a protective role in demyelinating diseases, not only downregulating the function of inflammatory cells but also promoting the survival of progenitors and differentiated oligodendrocytes (Molina-Holgado *et al.*, 2001).

Finally, the activation of cannabinoid receptors exerts protective effects on neurons and oligodendrocytes and suppresses chronic inflammatory responses through the attenuation of pro-inflammatory mediators. Therefore, cannabinoids might well modulate the progression of demyelinating diseases.

The effect of CB₂ receptor activation on neural stem/precursor cells

CB₂ receptors in the CNS

The past decade has seen a dramatic increase in our understanding of CB₂ cannabinoid receptor expression in the CNS, where CB₂ receptors display a more limited pattern of expression than CB₁ receptors (Pazos *et al.*, 2005; Van Sickle *et al.*, 2005; Gong *et al.*, 2006). CB₂ receptors are thought to be mainly expressed in the immune system

(Munro *et al.*, 1993); however, recent findings have clearly demonstrated that CB₂ receptors are also located in discrete neural cell populations (Van Sickle *et al.*, 2005), oligodendrocyte progenitors and mature cells (Molina-Holgado *et al.*, 2002), cerebellar granular cells (Skaper *et al.*, 1996), microglial cells (Benito *et al.*, 2003; Walter and Stella, 2004) and endothelial cells (Golech *et al.*, 2004). Moreover, cannabinoid CB₂ receptors have been identified in neural stem cells (NSCs) both *in vivo* and *in vitro*, and CB₂ selective cannabinoid agonists and antagonists modulate NSC formation and precursor cell proliferation through phosphoinositide-3 kinase/Akt and extracellular regulated kinase signalling (Palazuelos *et al.*, 2006; Arevalo-Martin *et al.*, 2007; Molina-Holgado *et al.*, 2007). Indeed, this pathway was previously shown to mediate cannabinoid-induced survival of oligodendrocyte progenitor cells deprived of trophic support *in vitro* (Molina-Holgado *et al.*, 2002).

Neural stem cells express CB₂ receptors in vivo

Some discrete regions of active neurogenesis are maintained in the adult mammalian brain, with the capacity to generate functional neurons. These neurogenic areas include the SVZ and the subgranular zone (SGZ) of the dentate gyrus in the hippocampus, and adult NSCs appear to be capable of proliferating and differentiating within these zones (for a review see Alvarez-Buylla and Lim, 2004). In both these areas, the SVZ and SGZ, functional CB₂ receptors have been identified in neural progenitor cells and their activation has been associated with NSC proliferation (Palazuelos *et al.*, 2006; Molina-Holgado *et al.*, 2007). Mounting interest has focused on the dual function of the endocannabinoid system on neurogenesis in health and disease (Galve-Roperh *et al.*, 2007). Hence, further studies will be necessary to determine how CB₂ signalling pathways participate in the regulation of neurogenesis during CNS development, and whether CB₂-associated signalling cascades are activated in neurodegenerative disorders.

The SGZ

Neural progenitor cells located in the SGZ of the hippocampus proliferate and give rise to immature neurons (Kempermann *et al.*, 2003), which become functional neurons within 4–6 weeks (Van Praag *et al.*, 2002). There is evidence that CB₂ receptors play an active role in the modulation of hippocampal neurogenesis. Indeed, hippocampal progenitors produce endocannabinoids in a developmentally regulated pattern (Fernandez-Ruiz *et al.*, 2000; Aguado *et al.*, 2005). Moreover, the expression of CB₂ receptors in the SGZ is restricted to neural progenitor cells (Palazuelos *et al.*, 2006). The presence of functional CB₂ receptors in SGZ progenitor cells was confirmed by assessing BrdU incorporation in response to HU-308 treatment in CB₂ KO animals and their wild-type (WT) littermates. Pharmacological blockage with the CB₂ antagonist SR-144528 blocked basal progenitor proliferation while HU-308 induced proliferation, suggesting that CB₂ signalling modulates progenitor cell proliferation in the SGZ (Palazuelos *et al.*, 2006).

The SVZ

In the SVZ, NSC proliferate and are a source of neurons and oligodendrocytes (Doetsch *et al.*, 1999; Menn *et al.*, 2006). CB₂ cannabinoid receptors are present in the postnatal rat SVZ and exogenous administration of selective CB₂ receptor agonists such as JWH-056 to newborn animals affects the development of this zone (Arevalo-Martin *et al.*, 2007). Additional studies confirmed that CB₂ receptors are expressed in the rat SVZ using PCR, western blotting and immunohistochemistry. This expression is somewhat complementary to that of the CB₁ receptor since CB₂ is predominantly expressed in polysialylated neural cell adhesion molecule (PSA-NCAM)-positive precursors, although there are a small number of stem cells that are immunoreactive for CB₂ receptors. Furthermore, CB₂ receptors affect SVZ function, since treatment with a selective agonist (JWH-056) increases the expression of PSA-NCAM. PSA-NCAM-expressing cells in the SVZ have been identified as migratory neuroblasts that enter the rostral migratory stream, as well as oligodendrocyte precursors that migrate towards the adjacent areas of the white matter (Doetsch *et al.*, 1999; Menn *et al.*, 2006). The signals controlling the physiology of postnatal SVZ development remain unknown, despite the fact that some candidates control these processes have been already identified (Lie *et al.*, 2004). These findings indicate that cannabinoids may provide such signals, and they suggest that both CB₁ and CB₂ receptors may be implicated in postnatal oligodendrogenesis.

Neural stem cells express CB₂ receptors in vitro

In vitro studies, using neurospheres (clonal cellular aggregates of neural stem cells/precursors cells), stem cell lines or primary cultures of NSC derived from embryonic and adult brain, have confirmed that cells proliferating *in vitro* express functional CB₂ receptors (Palazuelos *et al.*, 2006; Molina-Holgado *et al.*, 2007). Indeed, CB₂ receptors are expressed in PSA-NCAM-positive cells of the rat SVZ (Arevalo-Martin *et al.*, 2007). Accordingly, NSCs express fully functional CB₂ receptors and their activation promotes their proliferation leading to the generation of more neurospheres. Hence, CB₂ receptor activation could be involved in maintaining the self-renewal capacity of stem cells. Moreover, the expression of the stem cell marker Sox-2 is maintained through several passages in cultures stimulated with CB₂ agonists. Since the activation of CB₂ receptors does not produce any psychoactive effects, these results open the possibility to study whether neural stem cell behaviour could be manipulated *in vivo* through the administration of exogenous CB₂-selective agonists.

Collectively, these findings demonstrate that NSCs are targets for CB₂ agonists, and in conjunction with recent synthesis of non-psychotropic CB₂ agonists (Galve-Roperh *et al.*, 2006; Zhang *et al.*, 2007), this raises the possibility that CB₂ agonists could have the potential to promote brain repair. In fact, brain or spinal cord lesions activate stem/precursor cells and recruit new cells to the injured areas (Hallbergson *et al.*, 2003; Romanko *et al.*, 2004). Thus, promoting remyelination by endogenous progenitors or transplantation of new exogenous progenitors are promising

Figure 2 Points of interaction of CB₂ receptors with the pathogenesis of demyelinating diseases. The activation of CB₂ receptors decreases the deleterious inflammatory response that results in the death of both oligodendrocyte progenitors and mature oligodendrocytes in immune-mediated demyelinating pathologies. Also, CB₂ stimulation in oligodendroglial cells promotes their survival and therefore, CB₂ agonists may be useful in other non-immune-mediated demyelinating pathologies. In addition, the activation of CB₂ receptors may not only have an effect in protecting from demyelination but also, in promoting repair. In this sense, CB₂ agonists promote the proliferation of neural stem/precursor cells and increase the expression of migration-related molecules such as PSA-NCAM in the SVZ. Therefore, CB₂ receptor agonists could be therapeutic molecules that prevent the loss of myelin and promote the activation of the neural stem/precursor cells involved in the recovery of the myelin sheath. PSA-NCAM, polysialylated neural cell adhesion molecule; SVZ, subventricular zone.

therapeutic strategies for demyelinating diseases (Imitola *et al.*, 2003). Either way, CB₂ agonists could be a powerful tool to aid future therapies.

Conclusions

Resident immune and CNS cells express functional CB₂ receptors. The activation of CB₂ receptors results in the modulation of the inflammatory response, restraining one of the agents responsible for the progress of demyelination and neuronal death, the ultimate causes of the symptoms in pathologies such as MS and EAE. The modulation of inflammatory molecules through CB₂ receptors could also enhance remyelination, stimulating the survival of oligodendrocyte precursors and neural stem/precursor cells, and their development into mature oligodendrocytes.

However, the role of CB₂ in controlling demyelination and enhancing remyelination is not limited to autoimmune diseases and it is not restricted to the control of the immune system (Figure 2). Both in MS, EAE and other non-immune-mediated demyelinating diseases, the protective effect of CB₂ agonists on neural cells is a remarkable advantage. Moreover, CB₂ receptor activation may be a relevant strategy in cellular replacement. However, before proposing the usefulness of CB₂ agonists for myelin disorders, it is necessary to obtain a deeper understanding of what effects may be attributable to the activation of CB₂ receptors alone, and which are also due

to the participation of the CB₁ receptor. Furthermore, we must be aware of what effects may be mediated by other receptors, since there is increasing evidence that cannabinoids can induce certain effects independently of CB₁ or CB₂. Nevertheless, given our current understanding of CB₂ receptors and the pathogenesis of immune-mediated or other demyelinating disorders, these receptors seem to be of potential therapeutic interest.

Acknowledgements

EM-H is funded by grants from the Spanish Fondo de Investigaciones Sanitarias (04/2120) and from the Consejería de Sanidad de la Junta de Comunidades de Castilla-La Mancha (04061-00). FM-H is funded by The Wellcome Trust (UK). Personal support to AR-A was from the Consejería de Educación y Ciencia de la JCCM, and to B.N-G from the Ministerio de Educación y Ciencia (Programa Juan de la Cierva). CG is supported by Grants (SAF2004/0416) from Ministerio de Educación y Ciencia (Spain). We thank Dr Mark Sefton for critical reading of the manuscript and grammatical assistance.

Conflict of interest

The authors state no conflict of interest.

References

- Aguado T, Monory K, Palazuelos J, Stella N, Cravatt B, Lutz B *et al.* (2005). The endocannabinoid system drives neural progenitor proliferation. *FASEB J* 19: 1704–1706.
- Alvarez-Buylla A, Lim DA (2004). For the long run: maintaining germinal niches in the adult brain. *Neuron* 41: 683–686.
- Arevalo-Martin A, Vela JM, Molina-Holgado E, Borrell J, Guaza C (2003). Therapeutic action of cannabinoids in a murine model of multiple sclerosis. *Neuroscience* 23: 2511–2516.
- Arevalo-Martin A, Garcia-Ovejero D, Rubio-Araiz A, Gomez O, Molina-Holgado E, Molina-Holgado E (2007). Cannabinoids modulate OLIG2 and PSA-NCAM expression in the subventricular zone of postnatal rats through CB₁ and CB₂ receptors. *Eur J Neurosci*, e-pub ahead of print: doi:10.1111/j.1460-9568.2007.05782.
- Back SA, Han BH, Lou NL, Chricton CA, Xanthoudakis S, Tam J *et al.* (2002). Selective vulnerability of late oligodendrocyte progenitors to hypoxia-ischemia. *J Neurosci* 22: 455–463.
- Baerwald KD, Popko B (1998). Developing and mature oligodendrocytes respond differently to the immune cytokine interferon-gamma. *J Neurosci Res* 52: 230–239.
- Baker D, Pryce G, Croxford JL, Brown P, Pertwee RG, Huffman JW *et al.* (2000). Cannabinoids control spasticity and tremor in a multiple sclerosis model. *Nature* 404: 84–87.
- Baker D, Pryce G, Croxford JL, Brown P, Pertwee RG, Makriyannis A *et al.* (2001). Endocannabinoids control spasticity in a multiple sclerosis model. *FASEB J* 15: 300–302.
- Benito C, Nunez E, Tolon RM, Carrier EJ, Rabano A, Hillard CJ *et al.* (2003). Cannabinoid CB₂ receptors and fatty acid amide hydrolase are selectively over expressed in neuritic plaque-associated glia in Alzheimer's disease brains. *J Neurosci* 23: 11136–11141.
- Benito C, Romero JP, Tolon RM, Clemente D, Docagne F, Hillard CJ *et al.* (2007). Cannabinoid CB₁ and CB₂ receptors and fatty acid amide hydrolase are specific markers of plaque cell subtypes in human multiple sclerosis. *J Neurosci* 27: 2396–2402.
- Brosnan CF, Raine CS (1996). Mechanisms of immune injury in multiple sclerosis. *Brain Pathol* 6: 243–257.
- Cabral GA, Harmon KN, Carlisle SJ (2001). Cannabinoid-mediated inhibition of inducible nitric oxide production by rat microglial cells: evidence for CB₁ receptor participation. *Adv Exp Med Biol* 493: 207–214.
- Carayon P, Marchand J, Dussosoy D, Derocq JM, Jbilo O, Bord A *et al.* (1998). Modulation and functional involvement of CB₂ peripheral cannabinoid receptors during B-cell differentiation. *Blood* 92: 3605–3615.
- Carlisle SJ, Marciano-Cabral F, Staab A, Ludwick C, Cabral GA (2002). Differential expression of the CB₂ cannabinoid receptor by rodent macrophages and macrophage-like cells in relation to cell activation. *Int Immunopharmacol* 2: 69–82.
- Chang A, Nishiyama A, Peterson J, Prineas J, Trapp BD (2000). NG2-positive oligodendrocyte progenitor cells in adult human brain and multiple sclerosis lesions. *J Neurosci* 20: 6404–6412.
- Chia LS, Thompson JE, Moscarello MA (1983). Disorder in human myelin induced by superoxide radical: an *in vitro* investigation. *Biochem Biophys Res Commun* 117: 141–146.
- Clifford DB (1983). Tetrahydrocannabinol for tremor in multiple sclerosis. *Ann Neurol* 13: 669–671.
- Coopman K, Smith LD, Wright KL, Ward SG (2007). Temporal variation in CB₂R levels following T lymphocyte activation: evidence that cannabinoids modulate CXCL12-induced chemotaxis. *Int Immunopharmacol* 7: 360–371.
- Coraddu F, Sawcer S, Feakes R, Chataway J, Broadley S, Jones HB *et al.* (1998). HLA typing in the United Kingdom multiple sclerosis genome screen. *Neurogenetics* 2: 24–33.
- Corbin JG, Kelly D, Rath EM, Baerwald KD, Suzuki K, Popko B (1996). Targeted CNS expression of interferon-gamma in transgenic mice leads to hypomyelination, reactive gliosis and abnormal cerebellar development. *Mol Cell Neurosci* 7: 354–370.
- Correa F, Mestre L, Docagne F, Guaza C (2005a). Activation of cannabinoid CB₂ receptor negatively regulates IL-12p40 production in murine macrophages: role of IL-10 and ERK1/2 kinase signaling. *Br J Pharmacol* 145: 441–448.
- Correa F, Mestre L, Molina-Holgado E, Arevalo-Martin A, Docagne F, Romero E *et al.* (2005b). The role of cannabinoid system on immune modulation: therapeutic implications on CNS inflammation. *Mini Rev Med Chem* 5: 671–675.
- Croxford JL, Miller SD (2003). Immunoregulation of a viral model of multiple sclerosis using the synthetic cannabinoid R+WIN55, 212. *J Clin Invest* 111: 1231–1240.
- Dobbie MS, Hurst RD, Klein NJ, Surtees RA (1999). Upregulation of intercellular adhesion molecule-1 expression on human endothelial cells by tumour necrosis factor-alpha in an *in vitro* model of the blood-brain barrier. *Brain Res* 830: 330–336.
- Docagne F, Muñeton V, Clemente D, Ali C, Loria F, Correa F *et al.* (2007). Excitotoxicity in a chronic model of multiple sclerosis: neuroprotective effects of cannabinoids through CB₁ and CB₂ receptor activation. *Mol Cell Neurosci* 34: 551–561.
- Doetsch F, Caille I, Lim DA, Garcia-Verdugo JM, Alvarez-Buylla A (1999). Subventricular zone astrocytes are neural stem cells in the adult mammalian brain. *Cell* 97: 703–716.
- Ehrhart J, Obregon D, Mori T, Hou H, Sun N, Bai Y *et al.* (2005). Stimulation of cannabinoid receptor 2 (CB₂) suppresses microglial activation. *J Neuroinflammation* 2: 29.
- Eljaschewitsch E, Witting A, Mawrin C, Lee T, Schmidt PM, Wolf S *et al.* (2006). The endocannabinoid anandamide protects neurons during CNS inflammation by induction of MKP-1 in microglial cells. *Neuron* 49: 67–79.
- Ferguson B, Matyszak MK, Esiri MM, Perry VH (1997). Axonal damage in acute multiple sclerosis lesions. *Brain* 120: 393–399.
- Fernandez-Ruiz J, Berrendero F, Hernandez ML, Ramos JA (2000). The endogenous cannabinoid system and brain development. *Trends Neurosci* 23: 14–20.
- Fernandez-Ruiz J, Romero J, Velasco G, Tolon RM, Ramos JA, Guzman M (2007). Cannabinoid CB₂ receptor: a new target for controlling neural cell survival? *Trends Pharmacol Sci* 28: 39–45.
- Fujinami RS (1989). Immune responses against myelin basic protein and/or galactocerebroside cross-react with viruses: implications for demyelinating disease. *Curr Top Microbiol Immunol* 145: 93–100.
- Galiegue S, Mary S, Marchand J, Dussosoy D, Carriere D, Carayon S *et al.* (1995). Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. *Eur J Biochem* 232: 54–61.
- Galve-Roperh I, Aguado T, Palazuelos J, Guzman M (2007). The endocannabinoid system and neurogenesis in health and disease. *Neuroscientist* 13: 109–114.
- Galve-Roperh I, Aguado T, Rueda D, Velasco G, Guzman M (2006). Endocannabinoids: a new family of lipid mediators involved in the regulation of neural cell development. *Curr Pharm Des* 12: 2319–2325.
- Gerety SJ, Rundell MK, Dal Canto MC, Miller SD (1994). Class II-restricted T cell responses in Theiler's murine encephalomyelitis virus (TMEV)-induced demyelinating disease. VI. Potentiation of demyelination with and characterization of an immunopathologic CD4⁺ T cell line specific for an immunodominant VP2 epitope. *J Immunol* 152: 919–929.
- Ghosh S, Preet A, Groopman JE, Ganju RK (2006). Cannabinoid receptor CB₂ modulates the CXCL12/CXCR4-mediated chemotaxis of T lymphocytes. *Mol Immunol* 43: 2169–2179.
- Golech SA, McCarron RM, Chen Y, Bembry J, Lenz F, Mechoulam R *et al.* (2004). Human brain endothelium: coexpression and function of vanilloid and endocannabinoid receptors. *Brain Res Mol Brain Res* 132: 87–92.
- Gong JP, Onaivi ES, Ishiguro H, Liu QR, Tagliaferro PA, Brusco A *et al.* (2006). Cannabinoid CB₂ receptors: immunohistochemical localization in rat brain. *Brain Res* 1071: 10–23.
- Greter M, Heppner FL, Lemos MP, Odermatt BM, Goebels N, Laufer T *et al.* (2005). Dendritic cells permit immune invasion of the CNS in an animal model of multiple sclerosis. *Nat Med* 11: 328–334.
- Groves RW, Ross EL, Barker JN, MacDonald DM (1993). Vascular cell adhesion molecule-1: expression in normal and diseased skin and regulation *in vivo* by interferon gamma. *J Am Acad Dermatol* 129: 67–72.
- Haines JL, Terwedow HA, Burgess K, Pericak-Vance MA, Rimmler JB, Martin ER *et al.* (1998). Linkage of the MHC to familial multiple sclerosis suggest genetic heterogeneity. *Hum Mol Genet* 7: 1229–1234.
- Hallbergson AF, Gnatenco C, Peterson DA (2003). Neurogenesis and brain injury: managing a renewable resource for repair. *J Clin Invest* 112: 1128–1133.

- Hellings N, Gelin G, Medaer R, Bruckers L, Palmers Y, Raus J *et al.* (2002). Longitudinal study of antimyelin T-cell reactivity in relapsing-remitting multiple sclerosis: association with clinical and MRI activity. *J Neuroimmunol* **126**: 143–160.
- Horwitz MS, Evans CF, McGavern DB, Rodriguez M, Oldstone MB (1997). Primary demyelination in transgenic mice expressing interferon-gamma. *Nat Med* **3**: 1037–1041.
- Howlett AC, Mukhopadhyay S (2000). Cellular signal transduction by anandamide and 2-arachidonoylglycerol. *Chem Phys Lipids* **108**: 53–70.
- Imitola J, Snyder EY, Khoury SJ (2003). Genetic programs and responses of neural stem/progenitor cells during demyelination: potential insights into repair mechanisms in multiple sclerosis. *Physiol Genomics* **14**: 171–197.
- Johnson RT (1994). The virology of demyelinating diseases. *Ann Neurol* **36**: 54–60.
- Keirstead HS, Blakemore WF (1997). Identification of postmitotic oligodendrocytes incapable of remyelination within the demyelinated adult spinal cord. *Neuropathol Exp Neuro* **56**: 1191–1201.
- Keirstead HS, Blakemore WF (1999). The role of oligodendrocytes and oligodendrocyte progenitors in CNS remyelination. *Adv Exp Med Biol* **468**: 183–197.
- Kempermann G, Gast D, Kronenberg G, Yamaguchi M, Gage FH (2003). Early determination and long-term persistence of adult-generated new neurons in the hippocampus of mice. *Development* **130**: 391–399.
- Kennedy MK, Torrance DS, Picha KS, Mohler KM (1992). Analysis of cytokines mRNA expression in the central nervous system of mice with experimental autoimmune encephalomyelitis reveals that IL-10 mRNA expression correlates with recovery. *J Immunol* **149**: 2496–2505.
- Klegeris A, Bissonnette CJ, McGeer PL (2003). Reduction of human monocytic cell neurotoxicity and cytokine secretion by ligands of the cannabinoid-type CB₂ receptor. *Br J Pharmacol* **139**: 775–786.
- Klein TW, Lane B, Newton CA, Friedman H (2000). The cannabinoid system and cytokine network. *Proc Soc Exp Biol Med* **225**: 1–8.
- Konat GW, Wiggins RC (1985). Effect of reactive oxygen species on myelin membrane proteins. *J Neurochem* **45**: 1113–1118.
- Kroenke MA, Segal BM (2007). Th17 and Th1 responses directed against the immunizing epitope, as opposed to secondary epitopes, dominate the autoimmune repertoire during relapses of experimental autoimmune encephalomyelitis. *J Neurosci Res* **85**: 1685–1693.
- Kurtzke JF (1993). Epidemiologic evidence for multiple sclerosis as an infection. *Clin Microbiol Rev* **6**: 422–427.
- Langrish CL, Chen Y, Blumenschein WM, Mattson J, Basham B, Sedgwick JD *et al.* (2005). IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. *J Exp Med* **201**: 233–240.
- Lee SF, Newton C, Widen R, Friedman H, Klein TW (2001). Differential expression of cannabinoid CB₂ receptor mRNA in mouse immune cell subpopulations and following B cell stimulation. *Eur J Pharmacol* **423**: 235–241.
- Li J, Baud O, Vartanian T, Volpe JJ, Rosenberg PA (2005). Peroxynitrite generated by inducible nitric oxide synthase and NADPH oxidase mediates microglial toxicity to oligodendrocytes. *Proc Natl Acad Sci USA* **102**: 9936–9941.
- Lie DC, Song H, Colamarino SA, Ming GL, Gage FH (2004). Neurogenesis in the adult brain: new strategies for central nervous system diseases. *Annu Rev Pharmacol Toxicol* **44**: 399–421.
- Liuzzi GM, Riccio P, dal Canto MC (1995). Release of myelin basic protein-degrading proteolytic activity from microglia and macrophages after infection with Theiler's murine encephalomyelitis virus: comparison between susceptible and resistant mice. *J Neuroimmunol* **62**: 91–102.
- Lombard C, Nagarkatti M, Nagarkatti P (2007). CB₂ cannabinoid receptor agonist, JWH-015, triggers apoptosis in immune cells: potential role for CB₂-selective ligands as immunosuppressive agents. *Clin Immunol* **122**: 259–270.
- Lyman WD, Sonett JR, Brosnan CF, Elkin R, Bornstein MB (1989). Δ⁹-Tetrahydrocannabinol: a novel treatment for experimental autoimmune encephalomyelitis. *J Neuroimmunol* **23**: 73–81.
- Maestroni GJ (2004). The endogenous cannabinoid 2-arachidonoyl glycerol as *in vivo* chemoattractant for dendritic cells and adjuvant for Th1 response to a soluble protein. *FASEB J* **18**: 1914–1916.
- Maresz K, Carrier EJ, Ponomarev ED, Hillard CJ, Dittel BN (2005). Modulation of the cannabinoid CB₂ receptor in microglial cells in response to inflammatory stimuli. *J Neurochem* **95**: 437–445.
- Maresz K, Pryce G, Ponomarev ED, Marsicano G, Croxford JL, Shriver LP *et al.* (2007). Direct suppression of CNS autoimmune inflammation via the cannabinoid receptor CB₁ on neurons and CB₂ on autoreactive T cells. *Nat Med* **13**: 492–497.
- Matias I, Pochard P, Orlando P, Salzet M, Pestel J, Di Marzo V (2002). Presence and regulation of the endocannabinoid system in human dendritic cells. *Eur J Biochem* **269**: 3771–3778.
- Menn B, Garcia-Verdugo JM, Yaschine C, Gonzalez-Perez O, Rowitch D, Alvarez-Buylla A (2006). Origin of oligodendrocytes in the subventricular zone of the adult brain. *J Neurosci* **26**: 7907–7918.
- Merrill JE, Benveniste EN (1996). Cytokines in inflammatory brain lesions: helpful and harmful. *Trends Neurosci* **19**: 331–338.
- Merrill JE, Ignarro LJ, Sherman MP, Melinek J, Lane TE (1993). Microglial cell cytotoxicity of oligodendrocytes is mediated through nitric oxide. *J Immunol* **151**: 2132–2141.
- Mews I, Bergmann M, Bunkowski S, Gullotta F, Bruck W (1998). Oligodendrocyte and axon pathology in clinically silent multiple sclerosis lesions. *Mult Scler* **4**: 55–62.
- Miller JR, Burke A, Bever CT (1983). Occurrence of oligoclonal bands in multiple sclerosis and other CNS diseases. *Ann Neurol* **13**: 53–58.
- Molina-Holgado E, Vela JM, Arévalo-Martín A, Guaza C (2001). LPS/IFN-γ cytotoxicity in oligodendroglial cells: role of nitric oxide and protection by the anti-inflammatory cytokine IL-10. *Eur J Neurosci* **13**: 493–502.
- Molina-Holgado E, Vela JM, Arevalo-Martín A, Molina-Holgado F, Almazan G, Borrell J *et al.* (2002). Expression of cannabinoid CB₁ receptors in oligodendroglial cells: activation of PI-3K/Akt signaling pathway promotes cell survival. *J Neurosci* **22**: 9742–9753.
- Molina-Holgado F, Lledo A, Guaza C (1997). Anandamide suppresses nitric oxide and TNF-α responses to Theiler's virus or endotoxin in astrocytes. *NeuroReport* **8**: 1929–1933.
- Molina-Holgado F, Molina-Holgado E, Guaza C (1998). The endogenous cannabinoid anandamide potentiates interleukin-6 production by astrocytes infected with Theiler's murine encephalomyelitis virus by a receptor-mediated pathway. *FEBS Lett* **433**: 139–142.
- Molina-Holgado F, Molina-Holgado E, Guaza C, Rothwell NJ (2002). Role of CB₁ and CB₂ receptors in the inhibitory effects of cannabinoids on lipopolysaccharide induced nitric oxide release in astrocyte cultures. *J Neurosci Res* **67**: 829–836.
- Molina-Holgado F, Pinteaux E, Moore J, Molina-Holgado E, Gibson RM, Guaza C *et al.* (2003). Endogenous interleukin-1 receptor antagonist mediates anti-inflammatory and neuroprotective actions of cannabinoids in neurons and glia. *J Neurosci* **23**: 6470–6474.
- Molina-Holgado F, Rubio-Araiz A, Williams RJ, Moore JD, Arévalo-Martín A, García-Ovejero D *et al.* (2007). CB₂ cannabinoid receptors promote mouse neural stem cell proliferation. *Eur J Neurosci* **25**: 629–634.
- Munro S, Thomas KL, Abu-Shaar M (1993). Molecular characterization of a peripheral receptor for cannabinoids. *Nature* **365**: 61–65.
- Nunez E, Benito C, Pazos MR, Barbachano A, Fajardo O, Gonzalez S *et al.* (2004). Cannabinoid CB₂ receptors are expressed by perivascular microglial cells in the human brain: an immunohistochemical study. *Synapse* **53**: 208–213.
- Okuda Y, Sakoda S, Bernard CC, Fujimura H, Saeki Y, Kishimoto T *et al.* (1998). IL-6-deficient mice are resistant to the induction of experimental autoimmune encephalomyelitis provoked by myelin oligodendrocyte glycoprotein. *Int Immunol* **10**: 703–708.
- Olsson JE, Nilsson K (1979). Gamma globulins of CSF and serum in multiple sclerosis: isoelectric focusing on polyacrylamide gel and agar gel electrophoresis. *Neurology* **29**: 1381–1391.
- Ortega-Gutierrez S, Molina-Holgado E, Arevalo-Martín A, Correa F, Viso A, Lopez-Rodriguez ML *et al.* (2005). Activation of the endocannabinoid system as therapeutic approach in a murine model of multiple sclerosis. *FASEB J* **19**: 1338–1340.
- Pacher P, Bátkai S, Kunos G (2006). The endocannabinoid system as an emerging target of pharmacotherapy. *Pharmacol Rev* **58**: 389–462.
- Palazuelos J, Aguado T, Egia A, Mechoulam R, Guzman M, Galve-Roperh I (2006). Non-psychoactive CB₂ cannabinoid agonists stimulate neural progenitor proliferation. *FASEB J* **20**: 2405–2407.

- Panitch HS, Hirsch RL, Schindler J, Johnson KP (1987). Treatment of multiple sclerosis with gamma interferon: exacerbation associated with activation of the immune system. *Neurology* **37**: 1097–1102.
- Pazos MR, Núñez E, Benito C, Tolón RM, Romero J (2005). Functional neuroanatomy of the endocannabinoid system. *Pharmacol Biochem Behav* **81**: 239–247.
- Pizzi M, Sarnico I, Boroni F, Benarese M, Dreano M, Garotta G et al. (2004). Prevention of neuron and oligodendrocyte degeneration by interleukin-6 (IL-6) and IL-6 receptor/IL-6 fusion protein in organotypic hippocampal slices. *Mol Cell Neurosci* **25**: 301–311.
- Pope JG, Vanderlugt CL, Rahbe SM, Lipton HL, Miller SD (1998). Characterization of and functional antigen presentation by central nervous system mononuclear cells from mice infected with Theiler's murine encephalomyelitis virus. *J Virol* **72**: 7762–7771.
- Pryce G, Ahmed Z, Hankey DJR, Jackson SJ, Croxford JL, Pocock JM et al. (2003). Cannabinoids inhibit neurodegeneration in models of multiple sclerosis. *Brain* **126**: 2191–2202.
- Puffenbarger RA, Boothe AC, Cabral GA (2000). Cannabinoids inhibit LPS-inducible cytokine mRNA expression in rat microglial cells. *Glia* **29**: 58–69.
- Rauch HC, Montgomery IN, Hinman CL, Harb W, Benjamins JA (1987). Chronic Theiler's virus infection in mice: appearance of myelin basic protein in the cerebrospinal fluid and serum antibody directed against MBP. *J Neuroimmunol* **14**: 35–48.
- Rodriguez M, Lennon VA (1990). Immunoglobulins promote remyelination in the central nervous system. *Ann Neurol* **27**: 12–17.
- Rodriguez M, Lucchinetti C, Clark RJ, Yaksh TL, Markowitz H, Lennon VA (1988). Immunoglobulins and complement in demyelination induced in mice by Theiler's virus. *J Immunol* **140**: 800–806.
- Rodriguez M, Pavelko KD, McKinney CW, Leibowitz JL (1994). Recombinant human IL-6 suppresses demyelination in a viral model of multiple sclerosis. *J Immunol* **153**: 3811–3821.
- Rodriguez M, Quddus J (1986). Effect of cyclosporin A, silica quartz dust, and protease inhibitors on virus-induced demyelination. *J Neuroimmunol* **13**: 159–174.
- Romanko MJ, Rola R, Fike JR, Szele FG, Dizon M, Felling RJ et al. (2004). Roles of the mammalian subventricular zone in cell replacement after brain injury. *Prog Neurobiol* **74**: 77–99.
- Sanchez AJ, Gonzalez-Perez P, Galve-Roperh I, Garcia-Merino A (2006). *R*-(+)-[2,3-dihydro-5-methyl-3-(4-morpholinylmethyl)-pyrrolo-[1,2,3-de]-1,4-benzoxazin-6-yl]-1-naphthalenylmethanone (WIN-2) ameliorates experimental autoimmune encephalomyelitis and induces encephalitogenic T cell apoptosis: partial involvement of the CB(2) receptor. *Biochem Pharmacol* **72**: 1697–1706.
- Sheng WS, Hu S, Min X, Cabral GA, Lokensgard JR, Peterson PK (2005). Synthetic cannabinoid WIN55, 212-2 inhibits generation of inflammatory mediators by IL-1beta-stimulated human astrocytes. *Glia* **15**: 211–219.
- Shevach EM, Chang JT, Segal BM (1999). The critical role of IL-12 and the IL-12R beta 2 subunit in the generation of pathogenic autoreactive Th1 cells. *Springer Semin Immunopathol* **21**: 249–262.
- Schmidt S, Linington C, Zipp F, Sotgiu S, de Waal MR, Wekerle H et al. (1997). Multiple sclerosis: comparison of the human T-cell response to S100b and myelin basic protein reveals parallels to rat experimental autoimmune panencephalitis. *Brain* **120**: 1437–1445.
- Skaper SD, Buriani A, Dal Toso R, Petrelli L, Romanello S, Facci L et al. (1996). The ALIamide palmitoylethanolamide and cannabinoids, but not anandamide, are protective in a delayed postglutamate paradigm of excitotoxic death in cerebellar granule neurons. *Proc Natl Acad Sci USA* **93**: 3984–3989.
- Smith SH, Harris LS, Uwaydah IM, Munson AE (1978). Structure-activity relationships of natural and synthetic cannabinoids in suppression of humoral and cell-mediated immunity. *J Pharmacol Exp Ther* **207**: 165–170.
- Steinman L (1996). Multiple sclerosis: a coordinated immunological attack against myelin in the central nervous system. *Cell* **85**: 299–302.
- Takahashi JL, Giuliani F, Power C, Imai Y, Yong V (2003). Interleukin-1 β promotes oligodendrocyte death through glutamate excitotoxicity. *Ann Neurol* **53**: 588–595.
- Trapp BD, Peterson J, Ransahoff R, Rudick R, Mork S, Bo L (1998). Axonal transection in the lesions of multiple sclerosis. *N Engl J Med* **338**: 278–285.
- Trapp BD, Ransahoff R, Rudick R (1999). Axonal pathology in multiple sclerosis: relationship to neurologic disability. *Curr Opin Neurol* **12**: 295–302.
- Ungerleider JT, Andrysiak T, Faibanks L, Ellison GW, Myers LW (1987). Delta-9-THC in the treatment of spasticity associated with multiple sclerosis. *Adv Alcohol Subst Abuse* **7**: 39–50.
- Van Praag H, Schinder AF, Christie BR, Toni N, Palmer TD, Gage FH (2002). Functional neurogenesis in the adult hippocampus. *Nature* **415**: 1030–1034.
- Van Sickle MD, Duncan M, Kingsley PJ, Mouihate A, Urbani P, Mackie K et al. (2005). Identification and functional characterization of brainstem cannabinoid CB₂ receptors. *Science* **310**: 329–332.
- Vartanian T, Li Y, Zhao M, Stefansson K (1995). Interferon γ -induced oligodendrocyte cell death: implications for the pathogenesis of multiple sclerosis. *Mol Med* **1**: 732–743.
- Vela JM, Molina-Holgado E, Arevalo-Martín A, Almazan G, Guaza C (2002). Interleukin-1 regulates proliferation and differentiation of oligodendrocyte progenitor cells. *Mol Cell Neurosci* **20**: 489–502.
- Viviani B, Bartesaghi S, Gardoni F, Vezzani A, Behrens MM, Bartfai T et al. (2003). Interleukin-1 β enhances NMDA receptor-mediated intracellular calcium increase through activation of the Src family of kinases. *J Neurosci* **23**: 8692–8700.
- Walter L, Stella N (2004). Cannabinoids and neuroinflammation. *Br J Pharmacol* **141**: 775–785.
- Weiser S, Miu J, Ball HJ, Hunt NH (2007). Interferon-gamma synergises with tumour necrosis factor and lymphotoxin-alpha to enhance the mRNA and protein expression of adhesion molecules in mouse brain endothelial cells. *Cytokine* **37**: 84–91.
- Werner P, Pitt D, Raine CS (2001). Multiple sclerosis: altered glutamate homeostasis in lesions correlates with oligodendrocyte and axonal damage. *Ann Neurol* **50**: 169–180.
- Yamada M, Zurbriggen A, Fujinami RS (1990). The relationship between viral RNA, myelin-specific mRNAs and demyelination in central nervous system disease during Theiler's virus infection. *Am J Pathol* **137**: 1467–1479.
- Ye P, D'Ercole AJ (1999). Insulin-like growth factor I protects oligodendrocytes from tumor necrosis factor-alpha-induced injury. *Endocrinology* **140**: 3063–3072.
- Yuan M, Kiertscher SM, Cheng Q, Zoumalan R, Tashkin DP, Roth MD (2002). Delta 9-Tetrahydrocannabinol regulates Th1/Th2 cytokine balance in activated human T cells. *J Neuroimmunol* **133**: 124–131.
- Zhang M, Martin BR, Adler MW, Razdan RK, Jallo JI, Tuma RF (2007). Cannabinoid CB(2) receptor activation decreases cerebral infarction in a mouse focal ischemia/reperfusion model. *J Cereb Blood Flow Metab* **27**: 1387–1396.
- Zimmerman S, Zimmerman AM, Cameron IL, Laurence HL (1977). Delta1-tetrahydrocannabinol, cannabidiol and cannabinal effects on the immune response of mice. *Pharmacology* **15**: 10–23.